Immunopathogenesis and therapy of cutaneous T cell lymphoma

Authors:
  • SHStephen Hess
    Stephen Hess
  • SRStephen K. Richardson
    Stephen K. Richardson
  • SNSara Newton
    Sara Newton
  • LSLouise C. Showe
    Louise C. Showe
  • BBBernice M. Benoit
    Bernice M. Benoit
  • RURavi Ubriani
    Ravi Ubriani
  • CVCarmela C. Vittorio
    Carmela C. Vittorio
  • JJJacqueline M. Junkins-Hopkins
    Jacqueline M. Junkins-Hopkins
  • MWMaria Wysocka
    Maria Wysocka
  • ARAlain H. Rook
    Alain H. Rook

Abstract
Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of lymphoproliferative disorders caused by clonally derived, skin-invasive T cells. Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common types of CTCLs and are characterized by malignant CD4+/CLA+/CCR4+ T cells that also lack the usual T cell surface markers CD7 and/or CD26. As MF/SS advances, the clonal dominance of the malignant cells results in the expression of predominantly Th2 cytokines, progressive immune dysregulation in patients, and further tumor cell growth. This review summarizes recent insights into the pathogenesis and immunobiology of MF/SS and how these have shaped current therapeutic approaches, in particular the growing emphasis on enhancement of host antitumor immune responses as the key to successful therapy.

This publication has 82 references indexed in Scilit: